Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
114.42
+0.75 (+0.66%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
71
72
Next >
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
April 24, 2024
Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024.
Via
Benzinga
Investor Alert: Prepare for the Market Crash With These 3 Stocks
April 23, 2024
These are the low-beta and attractively valued stocks to buy for a market crash as they represent companies with strong fundamentals.
Via
InvestorPlace
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
April 23, 2024
These are the undervalued pharmaceutical stocks to buy as they have a deep clinical pipeline which will driven earnings and cash flow growth.
Via
InvestorPlace
Understanding Merck & Co's Position In Pharmaceuticals Industry Compared To Competitors
April 23, 2024
Via
Benzinga
Looking Into Merck & Co's Recent Short Interest
April 23, 2024
Via
Benzinga
3 Under-The-Radar Stocks With Positive Potential
April 21, 2024
Via
Talk Markets
Unveiling 17 Analyst Insights On Merck & Co
April 18, 2024
Via
Benzinga
Market Whales and Their Recent Bets on MRK Options
April 17, 2024
Via
Benzinga
When you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
April 11, 2024
Via
Chartmill
Understanding Merck & Co's Position In Pharmaceuticals Industry Compared To Competitors
April 08, 2024
Via
Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.
Via
Benzinga
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
April 17, 2024
When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.
Via
InvestorPlace
Exposures
Product Safety
3 Dow Stocks to Buy Now: Q2 Edition
April 16, 2024
Although the idea of Dow stocks to buy now is patently boring, that could be a positive attribute amid the current backdrop.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
April 16, 2024
Healthcare stocks disappointed again last week with the XLV down over 3% and up only 1.65 % YTD, in a continued downtrend since March 28.
Via
Talk Markets
Better Growth Play: Merck or The Vanguard Growth Index Fund?
April 15, 2024
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
Via
The Motley Fool
Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.
April 14, 2024
Being able to stop a drug's unwanted effects could lead to a larger market share.
Via
The Motley Fool
2 Dividend Stocks to Buy and Hold Forever
April 08, 2024
These dividends are about as safe as they come.
Via
The Motley Fool
Market Whales and Their Recent Bets on MRK Options
April 03, 2024
Via
Benzinga
1 New Green Flag for Moderna and Merck Stock
April 12, 2024
There's a new reason to believe that their joint projects are going well.
Via
The Motley Fool
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
April 12, 2024
We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.
Via
InvestorPlace
Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans
April 11, 2024
Moderna pauses plans for Kenya vaccine plant amid declining COVID-19 vaccine demand in Africa. Losses from unfulfilled orders prompt strategic shift. Efforts to finalize deal with Kenyan government...
Via
Benzinga
Exposures
COVID-19
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
April 11, 2024
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
Via
InvestorPlace
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
April 10, 2024
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the...
Via
Benzinga
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
April 10, 2024
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE:
Via
Benzinga
Why Is Moderna Stock Trading Higher On Tuesday?
April 09, 2024
Moderna stock jumps post AACR 2024 presentation of mRNA-4157 + Keytruda data in advanced HPV-negative head and neck carcinoma. Positive responses in the Phase 1 trial, with a 27.3% objective response...
Via
Benzinga
Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement
April 08, 2024
A popular and rewarding goal in investing is building a strong portfolio for retirement. These retirement stocks should help.
Via
InvestorPlace
Topics
Retirement
Exposures
Pension
Down 75%. Is Agenus Stock a Buy on the Dip?
April 08, 2024
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.
Via
The Motley Fool
The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024
April 07, 2024
Our economy is on the up and up, and investing is a must. Let's review the most undervalued S&P 500 stocks to buy in April.
Via
InvestorPlace
Topics
Economy
Stocks
Exposures
Economy
US Equities
10 Health Care Stocks Whale Activity In Today's Session
April 04, 2024
Via
Benzinga
Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data
April 04, 2024
eFFECTOR Therapeutics unveils Phase 2 KICKSTART trial results for tomivosertib with Keytruda in NSCLC patients. Tomivosertib shows modest activity, but no clear path forward. Zotatifin emerges as a...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
71
72
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.